IP/C/W/614/Add.4  
24 October  2016 
(16-5790) Page: 1/13 
Council for Trade -Related Aspects of  
Intellectual Property Rights  Original:  English  
 
  TECHNICAL COOPERATION ACTIVITIES: INFORMATION FROM  
OTHER INTERGOVERNMENTAL ORGANIZATIONS  
WORLD HEALTH ORGANIZATION (WHO)  
Addendum  
At its meeting of 7 -8 June 2016, the Council for TRIPS agreed to invite intergovernmental 
organization observers to the Counci l to update the information on their technical and financial 
cooperation programmes relating to the implementation of the TRIPS Agreement.  
 
The present document reproduces the information which has been received from the World Health 
Organization (WHO) by means of a communication dated 18 October 2016 . 
 
_______________  
 
 
1  INTRODUCTION  
1.  This communication summarizes the technical cooperation activities of the World Health 
Organization (WHO) in the area of public health, innovation and intellectual property tha t have 
taken place since t he submission of the last report in October  2015 (IP/C/W/609/Add.5) . The 
overall objective of WHO's technical cooperation is to strengthen the capacity of developing 
countries in the areas of health innovation, access to medicines  and management of intellectual 
property . WHO's technical cooperation is based o n its mandate derived from the Global Strategy 
and Plan of Action on Public Health, I nnovation and Intellectual Property as well as other  relevant 
resolutions of the World Heal th Assembly.  
2  THE GLOBAL ANTIBIOTIC RESEARCH AND DEVELOPMENT PARTNERSHIP  
2.  The Sixty -eighth World Health Assembly in 2015 adopted the Global Action Plan on 
Antimicrobial Resistance (GAP -AMR) . This required the WHO to propose options for the 
establishment of n ew partnerships to identify priorities for new treatments, diagnostics, and 
vaccines to fight resistant pathogens . In response to this mandate the Global Antibioti c Research 
and Development  Partnership  (GARDP)  was launched in May 2016, as a joint initiativ e by WHO and 
the Drugs for Neglected Diseases initiative  (DND i). GARDP is aiming  to develop new antibiotic 
treatments, promote their responsible use and ensure equitable access to these antibiotics . 
Over €2 million  of the €3 million  required for the incubation phase have been secured from the 
governments of Germany, the Netherlands, the United Kingdom , South Afric a, Switzerland, as well 
as from Médecins Sans Frontières ( MSF). GARDP will work closely with a ll global stakeholders in 
antibiotic R&D such as pharmaceutical and biotechnology companies, start -ups, academia, civil 
society and health authorities to develop new antibiotic treatments.  
3.  DNDi will host the incubation phase . The GARD P team is responsible for developing the 
business plan, fundraising, building scientific strategy, setting up the scientific working group, 
preparing for the creation on an independent entity and building a product pipeline . WHO will 
support GARD P in priority setting, developin g appropriate stewardship, and access  policies , 
report ing back to i ts Member States, secur ing close collabor ation with the AMR Secretariat  and IP/C/W/ 614/Add.4  
- 2 - 
  relevant WHO departments, including the Essential Medicines List team, and the Global Health R&D 
Observatory.  
4.  In the first instance, GARDP in collaboration with WHO will identify R&D gaps that are currently 
not addressed . In response, GARDP will identify and launch R&D projects to develop needed new 
therapeutic solutions with the potential for short -term fruition, su ch as improving regimes of 
existing antibiotics, while also building more transversal approaches to antibiotic drug discovery, 
including the recovery of knowledge and assets of forgotten, withdrawn, or abandoned antibiotics . 
Ultimately, it will develop a b roader portfolio of new antibiotics treatments . GARDP aims to have at 
least two projects that address urgent global health needs ready for implementation by the end of 
2016 and two more by the end of 2017.  
3  TRANSFER OF TECHNOLOGY AND LOCAL PRODUCTION  
5.  WHO co llaborated  closely  with the Ethiopian Government in developing and launching a 
National S trategy and Plan of Action for Pharmaceutical Manufacturing Development in Ethiopia 
(2015 -2025) . The report was launched jointly by the Deputy -Prime Minister of Ethiop ia and the 
Director -General of WHO in July 2015. Since the launch, WHO has been working with the Ethiopian 
Government in spearheading development partner support in the implementation  phase . Under 
strategic objective 5, the strategy and plan of action emph asizes the support for the development 
of a local cluster for the production of new active pharmaceutical ingredients .1 In line with the 
various strategic objectives of the  national strategy and plan of action, WHO provided support in 
conducting assessment s on the feasibility of local production of active pharmaceutical ingredients 
(API) in Ethiopia, as well as the prioritization of essential medicines for local production . The 
experience gained in Ethiopia in developing and implementation of the National Strategy a nd Plan 
of Action can be extended to other African countries.  
6.  In 2016 WHO, with support by the European Commission , published The role of intellectual 
property in local production in developing countries : opportunities and challenges2 as part of a  
wider project covering different aspects and challenges of local production and the conditions 
under which local production may increase access to essential medicines .3 The report focuses on 
the role of intellectual property in facilitating local producti on to ultimately improve access to 
medical products in low- and middle -income countries . 
7.  How a national intellectual property system is set up is important when considering options for 
local production of pharmaceuticals in developing countries . Using prac tical examples and patent 
landscapes, this report attempts to set out the various strategies and options available to facilitate 
local production . The report describes the options available to countries with a generic industry to 
design an intellectual pro perty system that is favourable for local production and potentially for 
public health . The report highlights the importance of transparent and fair patent administration 
systems using the example of access to patent information . The report exemplifies how  this can 
also support the use of certain pre -grant flexibilities to increase the space for local generic 
companies and facilitate local production.  
8.  The report contains patent landscapes identifying  the most relevant patents and in which 
countries they hav e been filed or granted  to showcase opportunities for local production in 
different product areas and countries . The products that were included in the landscape are: 
 Atazanavir , a protease inhibitor antiviral medicine indicated for  treatment of 
HIV infect ion; 
 The human papillomavirus (HPV) vaccine Gardasil , a quadrivalent recombinant vaccine 
for the prevention of cervical cancer and genital warts caused by HPV types 6, 11, 16 
and HPV vaccination ; 
 Imatinib , an essential medicine for the treatment of some ca ncers and tumours ; 
                                                
1 http://www.who.int/phi/publications/Ethiopia_strategy_local_poduction.pdf?ua=1  
2 http://www.who.int/phi/publications/int_prop_role_local_prod_opportunities -challenges.pdf?ua=1  
3 http://www.who.int/phi/publications/local _production/en  IP/C/W/ 614/Add.4  
- 3 - 
   Pegylated interferon alfa -2a, an antiviral medicine indicated for treatment of chronic 
hepatitis C ; 
 Raltegravir, an antiviral medicine indicated in combination with other antiretroviral 
agents for the treatment of HIV infection ; 
 Sitaglip tin, an antidiabetic drug indicated as an adjunct to diet and exercise to improve 
glycaemic control in adults with type 2 diabetes mellitus . 
4  THE WHO R&D BLUEPRINT FOR ACTION  TO PREVENT EPIDEMICS  
9.  WHO Member States welcomed the R&D Blueprint at the World Hea lth Assembly in May 2016. 
The Blueprint is a global strategy and preparedness plan that fosters R&D activities to prevent 
epidemics . The aim of the Blueprint is to rapidly make available effective tests, vaccines and 
medicines to save lives, prevent large scale epidemics and minimise socio -economic disruption of 
an outbreak.  
10.  Despite the lack of preparedness of the global health community to cope with the Ebola 
outbreak in West Africa in 2014, the Ebola experience has also demonstrated the possibility of 
substantially expediting R&D timelines . The WHO, along with guided by an international scientific 
advisory group board, and partners engaged in global forums, are collaborating to create a novel 
R&D model for emerging pathogens for which few or no medical tre atments exist . Progress that 
has been made so far includes identifying major bottlenecks to international collaboration, 
agreeing upon data sharing principles and exploring innovative approaches to conducting clinical 
trials.  
11.  There are three approaches cur rently being used to improve preparedness under the 
Blueprint.  These are aligned with the lessons learned during the 2014 -2016 Ebola epidemic and 
include : identifying priority infectious disease threats and gaps and priorities in research and 
development ; improving collaboration between stakeholders ; and promoting an enabling 
environment for the conduct of research and development during outbreaks . WHO efforts will help 
to maximize consistency, robustness and effectiveness of research efforts and interventi ons. These 
new approaches will significantly reduce the time between the identification of an outbreak and the 
deployment of new medical technologies to reach developing countries in a public health crisis to 
save lives and avoid full scale crisis.  
5  WHO SUB MISSION TO THE UN SG  HIGH LEVEL PANEL ON ACCESS TO MEDICINES  
12.  The 2016 WHO Submissio n to the UN S G High Level Panel on Access to Medicines summarized 
relevant WHO experience in access to medicines that relate to the current innovation system . In 
the submiss ion, WHO argues for an expansion of the Medicines Patent Pool, calls for greater 
transparency of the patent status of essential medicines and encouraged the High -Level Panel t o 
consider the question of how to draw the line between what advancements should be considered 
patentable and what is part of lifecycle management . The submission also presented  a number of 
WHO-led projects for consideration by the Panel , including:  
 the possibility of setting up a pooled fund for voluntary contributions toward 
pharmace utical R&D for neglected diseases;  
 the R&D Bluep rint for pathogens likely to cause severe outbreaks in the near future , for 
example, being able to respond to emerging pathogens with limited to no medical 
countermeasures , such as the 2014 -2015 outbreak of E bola, see paragraphs 9-10; 
 the joint WHO/DND i initiative on creating a Global Antibiotic R&D Partne rship (GARDP), 
see paragraphs 2 -4; 
 organizing a Fair Pricing Forum to provide a global platform for relevant stakeholders to 
discuss and develop effective st rategies towards universal health coverage . The 
underlying approach is to identify the most promising options and strategies to expand 
access to new medicines while ensuring that sufficient incentives remain for research 
and innovation, and that generic me dicines also remain on the market.  IP/C/W/ 614/Add.4  
- 4 - 
  6  DIRECT COUNTRY SUPPO RT 
13.  In collaboration with relevant international organizations, through its Headquarter, Regional 
and Country Offices, WHO provides technical and policy support in framing national policies, laws 
and re gulation s to favour application and management of intellectual property in a manner that 
maximizes health -related innovation and promotes access to health products and services . Such 
support is provided upon request to assist Member States in devis ing ways  to safeguard public 
health interests, while adhering to their obligations under i nternational trade agreements.  
14.  WHO responded in particular to a request received by Colombia during the World Health 
Assembly in 2016 on ensuring access to Imatinib, a cancer  treatment included in the 
WHO Essential Medicines List . PAHO/WHO supported some member countries on discussions 
around negotiations of new regional trade agreements and their potential impact on  health 
policies . PAHO/WHO also provided support to countries  in the implementation and use of TRIP S 
flexibilities to facilitate access for medicines.  
15.  Together with WTO, WIPO, and UNCTAD, WHO provided te chnical assistance to the 
South  African Department of Trade and Industry on the development of an Intellectual Pro perty 
Consultative Framework . A WHO expert attended a two -day working session with the 
Inter-Ministerial Committee on Intellectual Property providing input on the different elements of 
the Consultative Framework .4 Jointly with UNCTAD, WHO provided technica l assistance to Ethiopia 
on how to make use of their LDC st atus to foster local production.  
_______________  
 
 
 
                                                
4 http://www.thedti.gov.za/news2016/IPConsultativeFramework.pdf    
  IP/C/W/614/Add.4  
- 5 - 
 
ANNEX1  
Activity  Date  Location  Brief Description  Link to further details (if available)  
Intellectual Property to Meet 
South Africa 's Developmen tal 
Objectives National Workshop, 
WTO in collaboration with 
WHO, WIPO and UNCTAD  26-27 September  
2016 Pretoria, 
South  Africa  The Workshop aimed at the issues relating 
to the intersection between public health 
and intellectual property including patent 
examinations and review procedures and 
limitations to pat ent rights . It also 
considered the links between public health 
and policy dimensions including competition 
policy and rules and industrial polices.   
Pharmaceutical policies and 
rational use of medicin es 
multi-country consultation, 
WHO  7-11 September  
2016 Copenhagen, 
Denmark  The aim of the consultation is to bring 
together high -level academics, stakeholders 
and policy -makers to discuss current 
challenges and opportunities in 
pharmaceutical policies . The meeting 
focused  on reviewing and sharing effective 
governance strategies for improving access 
to medicines, while implementing the World 
Health Assembly Resolution 67.22 and 
high-price medicines – affordability and 
sustainable access – and consulting on the 
next steps in providing health technologies 
and pharmaceuticals (HTP) country support.  http:// www.euro.who.int/en/media -
centre/events/events/2015/09/phar
maceutical -policies -and-rational -
use-of-medicines -multicountry -
consultation  
Summer School on 
Pharmaceutical Pricing, the 
Austrian Health Institute in 
collaboration with WHO  29 August  – 
2 Septembe r 2016 Vienna, Austria  The summer school helped train high -level 
civil servants in the WHO European Region 
in shaping and implementing policies for 
pricing medicines . Participants learnt about 
medicine pricing across Europe, funding and 
reimbursement model s, methods for 
comparing and analyzing prices, and the 
benefits and limitations of various policies.  http://www.euro.who.int/en/health -
topics/Health -systems/health -
technologies -and-
medicines/news/news/2016/09/first -
of-its-kind-training -targets -
medicine -pricing -policies  
                                                
1 In English only.    
  IP/C/W/614/Add.4  
- 6 - 
 
Activity  Date  Location  Brief Description  Link to further details (if available)  
Annual meeting of the interim 
network for promoting 
cooperation for regulation of 
medical products in the SEA 
Region , WHO  17–18 August  2016 Bangkok, 
Thailand  The meeting discussed the timely access to 
safe and efficacious medical products of 
assured quality to achieve Universal Health 
Coverage . This Network will support the 
development of efficient and effective 
medical products regulatory system and 
promote the strengthening of the role of 
National Regulatory Authorities of each 
country in the SEA region through fostering 
collaboration , building trust and shar ing 
regulatory information.   
International Trade and Health 
Technical Conference (ITH), 
Ministry of Health Thailand , 
WHO-SEARO  7-11 August  2016 Bangkok, 
Thailand  The Ministry of Health Thailand organized 
the International Trade and Health 
Conference (ITH ) that covered various areas 
where the Trans -Pacific Partnership 
Agreement (TPP) would i mpact health . 
These include traditional medicines, herbs 
and genetic resource ; medicines, vaccines 
and biological products ; medical devices ; 
food; c osmetics ; t obacco ; a lcoholic 
beverages ; and health services . SEARO 
provided technical support in the area of 
traditional medicines and knowledge and 
genetic resource s.   
13th WIPO -WTO Colloquium for 
Teachers of Intellectual 
Property from Developing 
Countries, with participat ion 
from WHO  13-24 June 2016  Geneva, 
Switzerland  The aim of the WIPO -WTO Colloquium is to 
help teachers of IP from developing 
countries become more aware of the Geneva 
institutions, negotiations and other activities 
dealing with intellectual property law a nd 
policy, and to strengthen their countries' 
independent research, policy analysis and 
teaching in international intellectual property 
law and economics with its diverse policy 
contexts.     
  IP/C/W/614/Add.4  
- 7 - 
 
Activity  Date  Location  Brief Description  Link to further details (if available)  
WTO Academic Support 
Programme – Lectures on 
TRIPS in Summer Acade my at 
the Centre for WTO Studies, 
Indian Institute of Foreign 
Trade, with participation from 
WHO  30 May 2016 Delhi, India  This training course was sponsored by the 
Indian Government through the Indian 
Institute of Foreign Trade, New Delhi, in the 
form of a Summer Academy on trade law in 
cooperation with the World Trade Institute. 
It aimed at strengthening India's capacity on 
trade law.   
International Conference on IP 
and Counterfeit, Falsified and 
Substandard Drugs, 
WHO/Ministry of Health and 
Population/ Institut Français 
Égypte  29-30 May 2016 Cairo, Egypt  The themes discussed at the Conference 
included IP and patent issues in Egypt, as 
well as the role of law and law enforcement 
in controlling counterfeit, falsified and 
substandard drugs. Presentations we re 
made by representatives of the Government 
of Egypt, the WTO, French experts and 
private sector representatives. WHO 
contributed the public health perspective 
making a clear distinction between 
intellectual property and public health 
considerations.   
National consultation on 
Transitioning from MDGs to 
SDGs: Ensure healthy lives 
and promote well -being for all 
Indians at all ages, WHO, 
Indian Ministry of Health & 
Family Welfare  10-11 May 2016 New Delhi, India  The focus of the two -day consultation is to 
reflect on the successes and the lessons 
learnt from the Millennium Development 
Goals (MDG) era and the possible way 
forward for achieving the ambitious and 
inclusive agenda of SDGs in the health 
sector over the next 15 years. SEARO 
provided technical suppo rt on improving 
access to affordable medicines, vaccines and 
diagnostics.  http://www.searo.who.int/india/med
iacentre/events/2016/consultation_
MDG_SDG/en/    
  IP/C/W/614/Add.4  
- 8 - 
 
Activity  Date  Location  Brief Description  Link to further details (if available)  
The Use of Intellectual 
Property Rights' Flexibilities to 
Promote Local Pharmaceutical 
Production in Ethiopia, 
UNCTAD in collaboration with 
WHO 3-4 May 2016 Addis Ababa, 
Ethiopia  The objective of the Workshop is to enhance 
the understanding of participants of the 
interface of intellectual property and local 
pharmaceutical production. The Workshop 
was organized in response to the invitation 
to contribute to the implementation of the 
National Strategy and Plan of Action for 
Pharmaceutical Manufacturing Developmen t 
(2015 -2025) in collaboration with the World 
Health Organization. Topics for discussion 
included pharmaceutical trademarks, unfair 
competition and anti -counterfeiting 
measures.  http://unctad.org/meetings/en/Sessi
onalDocuments/tot_ip_2016_May_Wo
rkshopReport_EthiopiaIPPharma.pdf   
Regional Action plan for 
Hepatitis, WHO SEARO  26–28 April 2016 Jakarta, 
Indonesia  The presentations discussed the e ffective 
medicines and tools that have become 
available to prevent the development of 
advanced disease and reduce mortality in 
persons with chronic viral hepatitis B and C.   
Global Challenges Seminar on 
Patents and the WHO Model 
List of Essential Medicin es: 
Clarifying the Debate on IP 
and Access, WIPO, with 
participation from WHO  12 April 2016 Geneva, 
Switzerland  The seminar covered topics including patent 
protection and access to essential 
medicines, identifying patent status of 
essential medicines, ess ential medicine 
patent transparency and interventions for 
patented products. WHO presented its work 
on patent transparency.  http://www.wipo.int/meetings/en/de
tails.jsp?meeting_id= 39383  
Eighth WIPO -WTO Advanced 
Course on Intellectual Property 
for Government Officials, with 
participation from WHO  7-18 March  2016 Geneva, 
Switzerland  The main objective of the WIPO -WTO 
Advanced Course on Intellectual Property for 
Government Officials is to update 
government officials on the activities and 
instruments of WIPO and the WTO, and to 
provide a forum for them to exchange 
information and ideas with the 
two Secretariats and with a range of 
organizations based in Geneva.     
  IP/C/W/614/Add.4  
- 9 - 
 
Activity  Date  Location  Brief Description  Link to further details (if available)  
Regional Experts Consu ltation 
on Access to Affordable 
Medicines, Diagnostics and 
Vaccines, UNDP, ESCAP, 
UNAIDS, APN+, APCASO, WHO  15-17 March  2016 Bangkok, 
Thailand  The themes covered in the consultation 
included medicines, vaccines and 
diagnostics, policies for equitable acce ss, 
balancing trade and health, country and civil 
society organizations approaches and 
developing a pro -health agenda for national 
consultations.  https://unaids -
ap.org/2016/03/18/experts -call-for-
renewed -urgency -to-ensure -access -
to-affordable -medicines -in-asia 
Workshop on Intellectual 
Property and Public Health, 
WTO in collaboration with 
WHO and WIPO  17-18 February  
2016 Dubai , United 
Arab Emirates  The Workshop considered agreements 
relating to intellectual property and public 
health including TRIPS Agreement and the 
Doha Declaration. The different sessions 
considered patent roles for innovation and 
access in medical technologi es, and 
perspectives on the interplay between 
intellectual property and public health.   
Information Session on 
Determination of Equivalence 
for Pesticide -based Vector 
Control Products, FAO/WHO  1-2 February  2016 Geneva, 
Switzerland  The objectives of the s ession was to discuss 
the current FAO/WHO definition and criteria 
used for determining equivalence of 
pesticide active ingredients and formulations 
under the International Code of Conduct on 
Pesticide Management and the WHO 
equivalent process for evaluatio n of 
medicines, to understand impact of 
equivalence on the availability of 
pesticide -based vector control products and 
perspectives of various stakeholders in 
vector control.   
Licensing Policies of Public 
Research Institutions: 
Optimising Health Benefits , 
Institut Pasteur, WHO  14-15 January  
2016 Paris, France  The objective of the Workshop was to explore 
the role of licensing policies of academic 
research and public health institutions in 
assuring development, affordability and 
availability of new health p roducts.   
WHO Essential Medicines and 
Health technologies English 
Technical Briefing Seminar 
(TBS)  23-27 November  
2015 Geneva, 
Switzerland  Pharmaceutical Policies seminar aimed at 
people working on medicine issues in the 
pharmaceutical and health sector  
programmes in developing and transitional 
countries. The seminars provide an update 
on topics related to medicine quality, 
access, use, regulation, and innovation.  http://www.who.int/medicines/techn
ical_briefing/tbs/tbs_en_programme
_nov_2015/en/     
  IP/C/W/614/Add.4  
- 10 - 
 
Activity  Date  Location  Brief Description  Link to further details (if available)  
WTO Regional Workshop on 
Intellectual Property, Public 
Health and Priority Needs in 
collaboration with WHO  3-6 November  
2015 Abidjan, 
Ivory Coast  The Workshop aimed at providing 
participants with a better understanding of 
(i) the TRIPS Agreement; (ii) the linkages 
between the Intellectual Property regime 
and the access to the Public Health; and (iii) 
the WTO needs assessment process in the 
field of Intellectual Proper ty.  
5th WHO-WIPO -WTO joint 
Trilateral Symposium on 
Innovation and Access to 
Medicines; Learning from the 
Past, Illuminating the Future  28 October  2015 Geneva, 
Switzerland  The Trilateral Symposium reviewed the 
information base on access and innovation 
in medical technologies and identified 
possibilities and limitations for better 
integrating data in support of policy makers' 
future work.  https://www.wto.org/english/news_
e/news15 _e/trip_31aug15_e.htm  
WHO, WIPO and WTO 
Technical Workshop on 
"Patentability Criteria"  27 October  2015 Geneva, 
Switzerland  The Technical Workshop aimed at 
complementing the 28  October  2015 
Symposium (see below) through providing 
participants with practic al insights into how 
the main substantive patentability criteria 
are applied in practice at country level and 
how different interpretations can impact on 
public health.  https://www.wto.org/english/tratop
_e/trips_e/trilat_workshop15_e.htm     
  IP/C/W/614/Add.4  
- 11 - 
 
Activity  Date  Location  Brief Description  Link to further details (if available)  
WTO Workshop on Trade and 
Health for Capital -based 
officials from Developing 
Countries, in collaboration with 
WHO and WIPO  26-30 October  
2015 Geneva, 
Switzerland  The Workshop laid emphas is on building 
capacity to analyse and undertake policy 
choices in the area of intersection between 
trade and public health. Presentations, 
discussions and practical exercises therefore 
looked at relevant trade agreements as part 
of the wider action to add ress needs specific 
to public health. In particular, the Workshop 
covered key factors that impact on 
innovation and access in the pharmaceutical 
sector, including: Public health 
determinants; intellectual property rights; 
pricing and procurement policies; 
competition policy and rules; tariffs, quotas 
and licensing; and health services. A 
separate section dealt with regulatory 
issues, including the approval, quality 
control and effectiveness of medicines, the 
protection of clinical test data under the 
TRIPS Agreement and health -related 
measures in the TBT and SPS Committees.  https://www.wto.org/english/news_
e/news15_e/trip_12nov15_e.htm  
Pharmaceutical Pricing and 
Reimbursement Po licies: 
Challenges beyond the 
financial crisis, WHO  12-13 October  
2015 Vienna, Austria  The conference aimed to present 
on-the-frontier academic analysis as well as 
foster discussion of challenges in pricing and 
reimbursement policies. Among other topics, 
sofosbuvir and the reimbursement of highly 
innovative drugs were discussed.  http://www.who.int/medicines/news
/3rd_ppri_conf/en / 
Trade and the Right to Health 
in the context of 
Non-Communi cable Diseases, 
Ministry of Law and Human 
Rights in Indonesia, 
Indonesian Ministry of Law and 
Human Rights, WHO  6-9 October  2015 Batam, Indonesia  National Consultation was held to develop 
multisectoral coordination especially relating 
to the areas of trad e and commerce to 
ensure the right to health of the citizens of 
Indonesia in line with international and 
national obligations.     
  IP/C/W/614/Add.4  
- 12 - 
 
Activity  Date  Location  Brief Description  Link to further details (if available)  
Regional Meeting for 
Promoting Cooperation for 
Regulation in Trade of Medical 
Products, WHO -SEARO  22-24 September  
2015 New De lhi, India  Topics discussed included the need to 
develop a regulatory affairs network for 
cooperation, establishing a network to 
enhance information exchange and capacity 
building to adopt best practices and 
international standards and convening 
annual mee ting on National Medicines 
Regulatory Authorities.   
The 2nd Meeting on Access to 
Medicines under Universal 
Health Coverage in the 
Asia Pacific Region, WHO  17-18 September  
2015 Seoul, Republic 
of Korea  Presentation on hepatitis C and high -priced 
drugs. Sp ecifically, the presentation focused 
on strategies to expand access to viral 
hepatitis treatment in Mongolia.  
Speaker details: Managing intellectual 
property for access to viral hepatitis 
Medications - Peter Beyer, Senior Advisor, 
Public Health, Innovation  and Intellectual 
Property, WHO Headquarter 
(Skype  presentation).  http://www.wpro.who.int/essential_
medicines/documents/second_mtg_
access_to_medici nes_uhc/en/  
WHO Essential Medicines and 
Health technologies French 
Technical Briefing Seminar 
(TBS)  14-18 September  
2015 Geneva, 
Switzerland  Pharmaceutical Policies seminar aimed at 
people working on medicine issues in the 
pharmaceutical and health secto r 
programmes in developing and transitional 
countries.  http://www.who.int/medicines/techn
ical_briefing/tbs/fr/    
  IP/C/W/614/Add.4  
- 13 - 
 
Activity  Date  Location  Brief Description  Link to further details (if available)  
Regional Meeting on High -Cost 
and Strategic Medicines, WHO, 
PAHO  2-3 September  
2015 Santiago de 
Chile, Chile  The aim of the meeting was to analyze the 
impact of incorporating high -cost medicines 
into the health system; share experiences 
and lessons learned among different 
stakeholders and discuss strategies to 
improve access  and decrease the financial 
impact of the incorporation of high -cost 
medicines; and, explore the adoption of 
common strategies that may improve access 
to high -cost and strategic medicines in 
countries in Latin America and the 
Caribbean. The gathering reach ed some 
important conclusions including suggesting 
(1) PAHO Member States should consider a 
Resolution to the Executive Council on the 
subject to ensure comprehensive technical 
cooperation and work to facilitate access to 
high-cost and strategic medicines and 
(2) countries should establish 
comprehensive health and pharmaceutical 
policies and strategies that provide 
long-term and sustainable solutions to 
ensure access to life -saving medicines.  http://www.paho.org/hq/index.php?
option=com_content&view=article&i
d=11169%3Amedicamentoestrategi
cos-alto-
costo&catid=4669%3Anews -
hss&Itemid=39594&lang= en 
 
__________